At least 20 pps. I have told a close friend that my prediction is 50 or more within five years unless NBS is bought out this year or next. That pps would correspond to a market cap of about 1.5 billion. If the RENEW and PRESERVE trials are positive, the efficacy of PCT stem cells would be established. Partnerships would follow to explore other indications using PCT stem cells. Eventually there would be a study comparing cardiac injection of stem cells as was done in the Baxter RENEW study in contrast to coronary artery injection of stem cells as was done in the NBS PRESERVE study. I like the coronary artery approach available to cardiologists because it is technically more feasible than percutaneous or intrathoracic injections (10 intramyocardial injections into targeted areas of the heart tissue)that would require in most instances the expertise of a thoracic surgeon.
Anyway, my guess is that Baxter will make a tender offer for NBS after it has the results of its RENEW P3 study later this year. It would be speculation as to what pps Baxter might make a tender offer. My guess is it would be between 15 - 20.
News 
Market Data 
Discover 
